Aleix Prat, Director of the Clínic Barcelona Comprehensive Cancer Center at Barcelona Clinical Hospital, shared a post on LinkedIn:
“New article in Clinical Cancer Research AACR Journals
Pleased to share our new publication reporting results of pembrolizumab plus paclitaxel in non-luminal HR+/HER2- advanced breast cancer after ET+CDK4/6i, a setting where the role of immunotherapy is unknown.
This work stems from the SOLTI – TATEN trial, an academically driven study, and shows clear signs of clinical activity of the combination, supporting the biological rationale for combining chemotherapy with immune checkpoint inhibition in selected HR+ tumors and reinforcing the need for improved biomarker-based patient selection.
Congratulations to Benedetta Conte as lead first author, and to Eva Maria Ciruelos Gil and myself as co-PIs, together with all participating investigators and patients.
We are deeply grateful for the continued support of Fundación FERO, CRIS Contra el Cáncer and Asociación Española contra el Cáncer, which made the translational analyses of this study possible.
It is a pity that MSD decided not to continue funding the trial despite these encouraging signals of activity. However, we will continue to pursue other IO+chemo combinations in this setting…”
Article: Pembrolizumab and Paclitaxel in HR+/HER2− Breast Cancer with HER2-Enriched or Basal-Like Subtypes
Authors: Benedetta Conte; Fara Brasó-Maristany; Tomás Pascual, Cristina Hernando, Silvia Vázquez, Salvador Blanch, Mafalda Oliveira, Juan Antonio. Virizuela, Montserrat Muñoz, Elia Seguí, Adela Rodriguez Hernández, Maria Jesus. Vidal Losada, Patricia Galván, Oleguer Castillo, Paula Blasco, Manuel Alva, Nuria Chic, Esther Sanfeliu, Sara Cano-Crespo, Fernando Salvador, Guillermo Villacampa, Lorea Villanueva, Juan Manuel. Ferrero-Cafiero, Ana Vivancos, Aleix Prat, Eva Ciruelos.
Read the full article
Clinical Cancer Research
More posts featuring Aleix Prat